KR20110013563A - Preparation method of particles composed of chitosan and fatty acid for stabilization of vitamin c derivatives - Google Patents

Preparation method of particles composed of chitosan and fatty acid for stabilization of vitamin c derivatives Download PDF

Info

Publication number
KR20110013563A
KR20110013563A KR1020110006370A KR20110006370A KR20110013563A KR 20110013563 A KR20110013563 A KR 20110013563A KR 1020110006370 A KR1020110006370 A KR 1020110006370A KR 20110006370 A KR20110006370 A KR 20110006370A KR 20110013563 A KR20110013563 A KR 20110013563A
Authority
KR
South Korea
Prior art keywords
fatty acid
chitosan
vitamin
complex
derivative
Prior art date
Application number
KR1020110006370A
Other languages
Korean (ko)
Other versions
KR101107641B1 (en
Inventor
박성용
이건민
권태현
Original Assignee
(주)코스몰
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)코스몰 filed Critical (주)코스몰
Priority to KR1020110006370A priority Critical patent/KR101107641B1/en
Publication of KR20110013563A publication Critical patent/KR20110013563A/en
Application granted granted Critical
Publication of KR101107641B1 publication Critical patent/KR101107641B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

PURPOSE: A particle composition comprising hydrophilic chitosan chain and lipophilic fatty acid chain for stabilizing vitamin C derivative is provided to be used as a carrier of physiologically active material. CONSTITUTION: A chitosan-fatty acid solution composition contains chitosan-fatty acid complex, water, and vitamin C derivative. A method for preparing the chitosan-fatty acid solution composition comprises: a step of mixing chitosan solution and fatty acid; a step of raising temperature to dissolving the fatty acid and form a complex of chitosan amino acid group and fatty acid carbonyl group; a step of removing solvent and raising by 150-180°C to form an amide group; a step of washing and decompression-distilling and freeze-drying to obtain a chitosan-fatty acid amphiphilic complex powder; and a step of dissolving in a solvent and mixing with vitamin C derivative.

Description

비타민 C유도체 안정화를 위한 키토산-지방산 입자 제조 방법{Preparation method of particles composed of chitosan and fatty acid for stabilization of vitamin C derivatives}Preparation method of particles composed of chitosan and fatty acid for stabilization of vitamin C derivatives}

본 발명은 비타민C유도체를 안정화시키기 위한 친수성 키토산 사슬과 친유성 지방산 사슬로 구성된 입자 조성물에 관한 것으로, 키토산 아민기와 지방산 사슬간에 이온복합체를 형성하고, 고온에서 두사슬간의 아마이드반응을 유도하여 양친매성 조성물을 형성하는 기술에 관한 것이다. The present invention relates to a particle composition composed of a hydrophilic chitosan chain and a lipophilic fatty acid chain for stabilizing a vitamin C derivative, and forms an ion complex between a chitosan amine group and a fatty acid chain, and induces an amide reaction between two chains at a high temperature. A technique for forming a composition is disclosed.

비타민 C는 피부에 결합조직을 자극하고, 자외선 및 공해 같은 환경요인으로부터 피부조직 방어를 향상하며, 피부의 색소를 제거시키며, 항-유리 라디칼 기능을 갖는다. 특히, 유용한 생물학적 효과인 피부 진피층 내에서 콜라겐합성을 촉진하여 피부탄력성을 증대하고, 자외선 등에서 발생되는 유해산소를 제거하는 피부미백효과 등의 우수성으로 인하여 화장품 분야에서 각종 형태로 응용하기 위하여 여러 가지 방법이 제시되었다.Vitamin C stimulates connective tissue on the skin, enhances skin tissue defenses from environmental factors such as ultraviolet light and pollution, removes skin pigments, and has anti-free radical function. In particular, due to its superiority such as skin whitening effect of promoting collagen synthesis in skin dermal layer which is a useful biological effect and removing harmful oxygen generated from ultraviolet rays, etc. This has been presented.

비타민 C의 상기 생리화학적 이점에도 불구하고 일반적으로 화장품이나 의약품에 사용되는 비타민C는 빛이나 열에 의해 매우 약하고 분해되기 쉬운 단점을 가지고 있다. 따라서, 화장품에 배합하면 쉽게 변색되고 냄새가 변하는 등 안정성에 문제가 많아 업계에서는 비타민 C의 안정화 기술에 많은 연구 집중하고 있으나 큰 연구 성과를 이루지 못하고 있는 실정이다. 그러므로, 순수 비타민 C를 사용하지 못하고 비타민 C 유도체를 사용하거나 순수 비타민 C를 오일류에 분산시키거나 폴리올에 녹여서 사용함으로써 사용성의 한계를 지니고 있다.    Despite the physiological and chemical benefits of vitamin C, vitamin C, which is generally used in cosmetics or medicines, has the disadvantage of being very weak and easily degraded by light or heat. Therefore, when formulated in cosmetics, there are many problems in stability such as discoloration and odor change, but the industry concentrates on the stabilization technology of vitamin C, but does not achieve great research results. Therefore, it does not use pure vitamin C, but has a limit of usability by using a vitamin C derivative or by dispersing pure vitamin C in oils or dissolving it in a polyol.

비타민 C의 안정화를 위한 제재로서 대한민국특허 공고번호 92-10272호에서는 다상유화형 유액상 화장료를 이용하였고, 대한민국특허출원 제 98-53973호에서는 2-히드록시 프로필 싸이클로덱스트린을 이용한 유중수형 타입을 이용하였다.      As a preparation for stabilizing vitamin C, Korean Patent Publication No. 92-10272 used a multiphase emulsified emulsion cosmetic, and Korean Patent Application No. 98-53973 used a water-in-oil type using 2-hydroxypropyl cyclodextrin. It was.

미국특허 제6,10267호는 L-아스코르빈산과 함께 수용성 고분자가 용해된 수용액과 계면활성제를 혼합한 수용액의 혼합물을 오일에 투입하여 유화한 후 냉각함으로써 수용성 고분자와 L-아스코르빈산을 입자형태로 고형하하여 오일에 분산되도록 하는 방법을 제시하고 있다. U.S. Patent No. 6,10267 discloses a water-soluble polymer and L-ascorbic acid particles by cooling a mixture of an aqueous solution in which a water-soluble polymer is dissolved with L-ascorbic acid and an aqueous solution mixed with a surfactant, followed by emulsification and cooling. A method of solidifying in form to disperse in oil is proposed.

본 발명의 목적은 키토산과 지방산으로 구성된 양친성 고분자 합성에 있어, 기존 용매를 이용한 결합법이 아닌, 이온기 조절을 통한 두조성물의 복합체 형성 후 가온, 감압에 의해 결합을 하는 방법을 제공하는데 있다. An object of the present invention is to provide a method of binding by heating and decompression after the formation of a complex of two compositions through the control of ionic groups in the synthesis of an amphiphilic polymer composed of chitosan and fatty acids, rather than using a conventional solvent binding method. .

또한 본 발명은 비타민C 유도체의 항산화능력의 훼손이 크게 없이 안정하게 비타민 C유도체를 포획하여 생체내에서 분해없이 장기간 충분히 작용할 수 있는 자기입자형성성 복합체를 제공하는 것이다.In another aspect, the present invention is to provide a self-particle-forming complex that can capture the vitamin C derivatives stably without significant damage to the antioxidant capacity of the vitamin C derivatives and can function sufficiently for a long time without degradation in vivo.

또한 본 발명은 항산화능력이 크게 훼손되지 않은 비타민 C유도체 함입된 자기입자 형성성의 복합체를 제공하는 방법을 제공하는 것이다.In another aspect, the present invention is to provide a method for providing a vitamin C derivative-containing magnetic particle-forming complex is not significantly impaired antioxidant capacity.

본 발명은 친수성 키토산 사슬과 친유성 지방산 사슬로 구성된 조성물에 관한 것으로, 기존 용매방식의 합성방법을 사용하지 않고 키토산 아민기에 지방산 사슬의 복합체를 형성한 후 고온에서 두 복합체간의 아마이드반응을 일으켜 자기집합성 입자를 형성하는 방법에 관한 것이다. The present invention relates to a composition composed of a hydrophilic chitosan chain and a lipophilic fatty acid chain, and forms a complex of fatty acid chains in a chitosan amine group without using a conventional synthetic method. A method of forming particles.

또한 본 발명은 상기 자기집합성 입자내부에 비타민 C를 함입하여 항산화능력을 충분히 발휘할 수 있도록 하는 복합체를 제공하는 것이다.
In another aspect, the present invention is to provide a complex that can fully exhibit the antioxidant capacity by incorporating vitamin C in the self-assembly particles.

상기의 과제를 해결하기 위하여 많은 연구를 한 결과 본 발명자는 As a result of many studies to solve the above problems, the present inventors

(a) 키토산 용액에 지방산을 혼합하는 단계; (a) mixing a fatty acid into the chitosan solution;

(b) 상기 혼합물의 온도를 높여 지방산을 녹이고 키토산 아미노산기와 지방산의 카르보닐기와의 복합체 형성 하는 단계;(b) raising the temperature of the mixture to dissolve the fatty acid and to form a complex of the chitosan amino acid group and the carbonyl group of the fatty acid;

(c) 상기 복합체를 감압하에서 150~180℃로 올려 아마이드기를 형성하는 단계;(c) raising the complex to 150-180 ° C. under reduced pressure to form an amide group;

(d) 세척과정을 거쳐 냉동건조에의해 분말상태로 제조하는 단계;(d) preparing the powder by lyophilization through a washing process;

를 포함하여 제조된 것을 특징으로 하는 물질을 개발함으로써 이들이 양친매성을 가져 비타민 C를 포획하여 복합체를 형성함을 알게 되어 본 발명을 완성하게 되었다.
By developing a material characterized in that the production, including that they have the amphipathy to capture vitamin C to form a complex to complete the present invention.

본 발명에서 사용되는 비타민 C 유도체(ethyl ascorbyl ether)는 통상의 비타민 C 유도체라면 제한이 없지만, 더욱 좋게는 본 발명에서는 비타민 C의 3위치 수산기(水酸基)를 Ethoxy기로 치환한 화합물이며, 비타민 C 유도체의 안정성의 경우 순수 비타민 C 자체에 비해서 개선되었지만 새로운 안정화 방법에 의해 개선될 여지를 가지고 있으며 본 발명에서는 천연다당류인 키토산과 지방산을 이용한 입자를 제조하여 안정성을 도모하고자 한다. The vitamin C derivative (ethyl ascorbyl ether) used in the present invention is not limited as long as it is a conventional vitamin C derivative. More preferably, in the present invention, a compound in which a 3-position hydroxyl group of vitamin C is substituted with an Ethoxy group, and a vitamin C derivative In the case of the stability of the improved compared to the pure vitamin C itself, but there is room for improvement by a new stabilization method and in the present invention to prepare the particles using the natural polysaccharides chitosan and fatty acids to improve the stability.

비타민 C 유도체의 안정성 향상을 위해 사용되는 키토산은 자연계에서 셀룰로오스(cellulose) 다음으로 풍부한 키틴의 탈아세틸화된 형태로서, 게, 새우, 가재 등의 갑각류로부터 얻어지는 키틴을 탈아세틸화시켜 얻은 D-글루코사민의 단당류 또는 이당류가 모노머로 중합되어 있는 폴리사카라이드계 생체고분자 물질로 β-(1,4)-2-amino-2-deoxy-D-glucopyranose의 기본단위를 가진다.   Chitosan, which is used to improve the stability of vitamin C derivatives, is the deacetylated form of chitin, which is rich after cellulose in nature, and D-glucosamine obtained by deacetylating chitin obtained from shellfish such as crabs, shrimp, and crayfish. Is a polysaccharide-based biopolymer in which a monosaccharide or a disaccharide is polymerized with a monomer and has a basic unit of β- (1,4) -2-amino-2-deoxy-D-glucopyranose.

본 발명에서의 소수성 부분인 지방산은 유지의90% 이상을 차지하고 있으며 탄소사슬에 카르복실시기가 결합되어 있는 구조로 되어있다. 그 골격을 이루는 탄소수와 이중결합수에 따라 명칭이 결정 된다.  Fatty acid, which is a hydrophobic part in the present invention, occupies 90% or more of fats and oils, and has a structure in which a carboxyl group is bonded to a carbon chain. The name is determined by the number of carbons and double bonds forming the skeleton.

- 탄소수 12개 : 라우린산 (lauric acid) 12 carbon atoms: lauric acid

- 탄소수 16개 : 팔미틴산 (palmitic acie) 16 carbon atoms: palmitic acid

- 탄소수 18개 : 스테아린산 (stearic acid) -18 carbon atoms: stearic acid

- 탄소수 18개, 이중결합1개 : 올레인산 (oleic acid) -18 carbon atoms, 1 double bond: oleic acid

- 탄소수 18개, 이중결합2개 : 리놀레인산 (linoleic acid)  -18 carbon atoms, 2 double bonds: linoleic acid

- 탄소수 18개, 이중결합3개 : 리놀레닉산 (linolenic acid)  -18 carbon atoms, 3 double bonds: linolenic acid

- 탄소수 20개, 이중결합4개 : 아라키도닉산 (arachidonic acid)  20 carbon atoms, 4 double bonds: arachidonic acid

따라서 상기 친수성과 소수성을 동시에 가지고 있는 양친성 고분자는 수용액상에서 계면에너지의 안정화를 위해 소수성 블록간의 상호작용을 통해 자기집합체를 형성하게 된다. 양친성 고분자에 의해 형성된 고분자 입자는 친수성 및 소수성의 정도에 따라 입자의 크기, 분포, 유동학적 성질 및 열역학적 안정성 등이 다르게 나타나는 것으로 알려져 있으며 내부에 쉽게 약물을 포집시켜 효과적인 약물전달체로 이용할 수 있다. Therefore, the amphiphilic polymer having both hydrophilicity and hydrophobicity forms a self-assembly through interaction between hydrophobic blocks to stabilize interfacial energy in an aqueous solution. The polymer particles formed by the amphiphilic polymer are known to exhibit different sizes, distributions, rheological properties, and thermodynamic stability depending on the degree of hydrophilicity and hydrophobicity.

다당류 양친성 고분자의 자기집합에 관련한 특허를 살펴보면 대한민국특허출원 제 10-2001-0049772에서는 자기집합체를 형성하는 항암제와 친수성 키토산으로 구성되는 복합체를 제조하였으며, 10-2003-0048240 및 10-2006-0003468에서도 소수성 담즙산, 친수성 키토산으로 구성되는 자기집합체를 형성하는 복합체를 제조하였는데 이들을 통해 자기집합체가 항암제를 포함한 다양한 소수성 약물 및 치료용 단백질을 효과적으로 봉입시킬 수 있어 의료용 약물전달체로서 유용하게 사용될 수 있음을 확인할 수 있다.Looking at patents related to self-assembly of polysaccharide amphiphilic polymers, Korean Patent Application No. 10-2001-0049772 prepared a complex composed of an anticancer agent and a hydrophilic chitosan to form a self-assembly, and 10-2003-0048240 and 10-2006-0003468 Also prepared a complex that forms a self-assembly consisting of hydrophobic bile acids and hydrophilic chitosan, through which the self-assembly can effectively encapsulate various hydrophobic drugs and therapeutic proteins, including anticancer drugs, and thus can be useful as medical drug carriers. Can be.

대한민국특허출원 제10-2005-0102307에서는 친수성을 가지는 천연 다당류 고분자와 소수성 화합물을 포함하는 수화 겔 자기 집합체를 나노캐리어로 이용하여 활성물질을 안정화시키는 방법을 나타내었다. 대한민국특허출원 제 10-2003-0005472에서는 질산암모늄을 산화환원 개시제로 사용하여 래디컬화된 키토산에 PNIPAAm을 그라프트 공중합시켜 온도민감성을 갖는 다당류 공중합체를 제조하였다. PNIPAAm과 같은 온도 민감성 고분자는 고분자 주쇄에 결합되어 있는 친수성 또는 소수성 부분의 존재비율에 따라 하한임계온도가 변하게 되는데, 이에 키토산을 결함시킴으로서 상전이 온도의 변화를 확인하고 또한 생체적합성을 부여하여 수화겔 형태로써 의료용 온도 감응성 고분자로의 응용 가능성을 확인하였다. Korean Patent Application No. 10-2005-0102307 shows a method of stabilizing an active material using a hydrogel self-assembly including a hydrophilic natural polysaccharide polymer and a hydrophobic compound as a nanocarrier. In Korean Patent Application No. 10-2003-0005472, a polysaccharide copolymer having temperature sensitivity was prepared by graft copolymerization of PNIPAAm on radicalized chitosan using ammonium nitrate as a redox initiator. Temperature-sensitive polymers such as PNIPAAm change the lower critical temperature according to the abundance ratio of hydrophilic or hydrophobic moieties bound to the polymer backbone. The applicability to the medical temperature sensitive polymer was confirmed.

상기 특허들에서 자기집합체를 이루는 약물전달용 양친성 고분자를 살펴보면 약물의 운반이 인체에서 이루어지는 것을 감안할 때 생체친화성이 우수한 천연다당류인 키토산으로 구성된 것을 확인할 수 있다. Looking at the amphiphilic polymer for drug delivery forming the self-assembly in the above patents, it can be seen that it is composed of chitosan, a natural polysaccharide having excellent biocompatibility, considering that the drug is transported in the human body.

이에 본 발명자들은, 비타민 C 유도체를 안정화하기 위하여 항산화성이 우수한 친수성 키토산 주쇄에 소수성 지방산을 그라프트하는 방법을 연구하던 중 기존 용매에 의한 합성방법을 대신하여 단순히 키토산과 소수성 지방산간의 이온성 복합체형성 후 150~180℃에서 아마이드결합이 형성되는 것을 발견하고 상기 방법에 의해 얻어진 물질을 외부의 자극에 대해 비타민 C 유도체의 안정성을 확인하고 본 발명을 완성하게 되었다.
The present inventors, while studying a method of grafting hydrophobic fatty acid to the hydrophilic chitosan backbone with excellent antioxidant properties to stabilize the vitamin C derivatives, instead of the conventional synthetic method using a solvent, an ionic complex between chitosan and hydrophobic fatty acid After formation, the amide bond was formed at 150-180 ° C., and the substance obtained by the above method was confirmed the stability of the vitamin C derivative against external stimulation and completed the present invention.

이상에서 살펴본 바와 같이, 본 발명은 빛이나 열에 의해 매우 약하고 분해되기 쉬운 단점을 가지는 비타민 C 유도체를 키토산-지방산 복합체를 사용하여 입자안에 함입시켜 안정성을 향상하는 방법을 제공하는 효과가 있으며 본 발명에 따른 키토산-지방산 복합체는 생리활성물질을 안정화하는 화장품 원료로 유용하게 사용될 수 있다. 또한 통상적으로 비타민C의 라디칼 활성도 등이 크게 감소하지 않는 등의 자기응집성 복합체를 사용하여도 그 효과는 유지하고 있음을 알 수 있다.As described above, the present invention has an effect of providing a method of improving stability by incorporating a vitamin C derivative having a disadvantage of being very weak and easily decomposed by light or heat into particles using a chitosan-fatty acid complex. The chitosan-fatty acid complex according to the present invention can be usefully used as a cosmetic raw material to stabilize the bioactive substance. In addition, it can be seen that the effect is maintained even when the self-aggregating complex such as radical activity of vitamin C is not greatly reduced.

본 발명의 단순한 변형 내지 변경은 이 분야의 통상의 지식을 가진 자에 의하여 용이하게 이용될 수 있으며, 이러한 변형이나 변경은 모두 본 발명의 영역에 포함되는 것으로 볼 수 있다.
Simple modifications and variations of the present invention can be readily used by those skilled in the art, and all such variations or modifications can be considered to be included within the scope of the present invention.

도 1은 본 발명에 따른 키토산 단량체-지방산 복합체 형성에 대한 분자모식도를 도시한 것이다.Figure 1 shows a molecular diagram for the formation of chitosan monomer-fatty acid complex according to the present invention.

이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되어서는 안된다.
Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention, and the scope of the present invention should not be construed as being limited by these examples.

실시예Example 1 내지 5:  1 to 5:

14.7ml의 증류수와 0.3ml의 염산으로 구성된 용액에 키토산(Mw=30만) 0.6g을 녹이고, 0.6 부터 3 g까지 다양한 중량분율로 지방산(라울릭 산)을 표 1에 기재된 함량으로 추가적으로 넣고 60℃로 올린 후 지방산을 30분간 녹인다. 혼합된 키토산과 지방산용액을 60℃에서 1시간동안 감압하면서 교반하여 증류수를 제거한 후, 키토산과 용융된 지방산을 170℃로 올려 10분동안 감압하에서 교반한 후 상온에서 식힌다. 제조된 복합체를 과량의 아세트산과 증류수에 차례로 넣어 세척해준 후 냉동건조하여 분말상을 얻는다. 얻어진 분말상의 아미드기 형성은 IR 및 H1-NMR을 이용하여 확인하였다.Dissolve 0.6 g of chitosan (Mw = 300,000) in a solution consisting of 14.7 ml of distilled water and 0.3 ml of hydrochloric acid, and add fatty acids (lauric acid) in the amounts shown in Table 1 in various weight fractions from 0.6 to 3 g. After raising to ℃ ℃ to dissolve fatty acids for 30 minutes. After distilled water was removed by stirring the mixed chitosan and fatty acid solution at 60 ° C. under reduced pressure for 1 hour, the chitosan and the dissolved fatty acid were raised to 170 ° C. and stirred for 10 minutes under reduced pressure, and then cooled at room temperature. The prepared complex is washed in turn with excess acetic acid and distilled water, and then lyophilized to obtain a powder form. Formation of the obtained powdery amide group was confirmed using IR and H1-NMR.

본 발명에서 제조한 중합체에 의해 형성된 나노자기집합체의 입자 형성유무 및 크기를 확인하기 위하여, 제조된 중합체를 수용액에 분산시킨 후 입자의 형성 유무를 관찰하였다.
In order to confirm the particle formation and size of the nano-magnetic assembly formed by the polymer prepared in the present invention, the polymer was dispersed in an aqueous solution and then observed to form particles.

Figure pat00001
Figure pat00001

실시예Example 6 내지 10 :  6 to 10:

비타민 C 유도체와 포집 및 방출 능력을 확인하기 위하여 실시예 1내지 5에서 제조된 키토산-지방산 중합체 1g을 1ml의 에탄올에 비타민 C유도체 1g을 혼합한 용액에 넣고 교반한 후 증류수에 넣어 입자를 생성시킨다. 포집율을 알아보기 위하여 원심분리 필터를 사용하여 포집되지 않은 비타민 C 유도체를 분리하였으며, 비타민 C 유도체의 양을 고성능 액체 크로마트그래피(HPLC)를 사용하여 측정하였다. In order to check the vitamin C derivatives and the capturing and releasing ability, 1 g of the chitosan-fatty acid polymer prepared in Examples 1 to 5 was added to 1 ml of ethanol in a solution containing 1 g of vitamin C derivatives, stirred, and then put into distilled water to form particles. . In order to determine the collection rate, uncaptured vitamin C derivatives were separated using a centrifugal filter, and the amount of vitamin C derivatives was measured using high performance liquid chromatography (HPLC).

Figure pat00002
Figure pat00002

이를 통해 결정된 비타민 C 유도체의 포집 효율은 [표 2]에 나타내었다.The capture efficiency of the vitamin C derivatives determined through this is shown in [Table 2].

Figure pat00003
Figure pat00003

실시예Example 11 내지 15: 11 to 15:

본 발명에서 제조한 복합체의 열적 안정성을 시험하기위하여, 실시예 1내지 5에서 제조된 용액을 25℃, 45℃의 항온조에서 불투명 초자 용기에 담아 2주 동안 보관하고, 보관 후 잔존하는 비타민 C 유도체의 양을 고성능 액체 크로마트그래피(HPLC)를 사용하여 측정하였다. 각각의 잔존율은 아래의 식에 의해 결정하였다.  In order to test the thermal stability of the composite prepared in the present invention, the solution prepared in Examples 1 to 5 was stored in an opaque glass container in a constant temperature bath at 25 ℃, 45 ℃ stored for 2 weeks, the vitamin C derivative remaining after storage The amount of was measured using high performance liquid chromatography (HPLC). Each residual rate was determined by the following formula.

Figure pat00004
Figure pat00004

Figure pat00005
Figure pat00005

실시예Example 16,  16, 비교예Comparative example 1 내지 2: 1 to 2:

본 발명에서 제조한 복합체의 자유라디칼 소거능력을 다음과 같이 측정하였다. 구체적으로는 1,1-디페닐-2-피크릴-히드라진(DPPH)의 방법을 사용하여 측정하였다. DPPH는 비교적 안정한 라디칼로서 517nm에서 최대 흡광을 보이며, 라디칼 소멸시 흡광성을 잃는다.  The free radical scavenging ability of the composite prepared in the present invention was measured as follows. Specifically, it measured using the method of 1, 1- diphenyl- 2-picryl- hydrazine (DPPH). DPPH is a relatively stable radical, exhibiting maximum absorption at 517 nm and losing absorbance upon radical disappearance.

상기 실시예 3용액을 96웰 플레이트의 각 웰에 100μl씩 넣었다. 여기에 DPPH용액을 10μl씩 첨가한 다음 상온에서 30분간 방치한 후 마이크로 플레이트 리이더를 사용하여 517nm에서의 흡광도를 측정하였다. 이때 대조군으로는 실시예 3용액과 같은 농도의 키토산 및 비타민 C 유도체 각각의 용액 100μl를 넣은 것을 사용하였다.The solution of Example 3 was placed in 100 μl of each well of a 96 well plate. 10 μl of DPPH solution was added thereto, followed by standing at room temperature for 30 minutes, and then the absorbance at 517 nm was measured using a microplate reader. In this case, 100 μl of a solution of each of chitosan and vitamin C derivatives having the same concentration as in Example 3 was used.

Figure pat00006
Figure pat00006

Claims (2)

아마이드기가 형성된 키토산-지방산 복합체, 물 및 비타민C 유도체를 포함하는 비타민 C유도체 함유 키토산-지방산 복합체 용액 조성물.
A chitosan-fatty acid complex-containing chitosan-fatty acid complex containing water, and a vitamin C derivative containing chitosan-fatty acid complex solution composition.
하기 단계로 제조하는 것을 특징으로 하는 비타민 C유도체 함유 키토산-지방산 복합체 용액 조성물.
(a) 키토산 용액에 지방산을 혼합하는 단계;
(b) 상기 혼합물의 온도를 높여 지방산을 녹이고 키토산 아미노산기와 지방산의 카르보닐기와의 복합체 형성 하는 단계;
(c) 상기 복합체를 감압하에서 용매를 제거하고 150~180℃로 올려 아마이드기를 형성하는 단계;
(d) 세척 후 감압 증류 및 동결건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 키토산-지방산 양친성 복합체 분말을 제조하는 단계; 및
(e) 상기 키토산-지방산 양친성 복합체를 용해하는 용매에 녹인 후 비타민C유도체를 혼합하여 물에 분산시켜 입자를 형성하는 단계
Vitamin C derivative-containing chitosan-fatty acid complex solution composition, characterized in that prepared in the following steps.
(a) mixing a fatty acid into the chitosan solution;
(b) raising the temperature of the mixture to dissolve the fatty acid and to form a complex of the chitosan amino acid group and the carbonyl group of the fatty acid;
(c) removing the solvent under reduced pressure and raising the complex to 150 to 180 ° C to form an amide group;
(d) preparing a chitosan-fatty acid amphiphilic composite powder by additional processes such as vacuum distillation and lyophilization or spray drying after washing; And
(e) dissolving the chitosan-fatty acid amphiphilic complex in a solvent to dissolve the vitamin C derivatives and dispersing it in water to form particles
KR1020110006370A 2011-01-21 2011-01-21 Preparation method of particles composed of chitosan and fatty acid for stabilization of vitamin C derivatives KR101107641B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020110006370A KR101107641B1 (en) 2011-01-21 2011-01-21 Preparation method of particles composed of chitosan and fatty acid for stabilization of vitamin C derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020110006370A KR101107641B1 (en) 2011-01-21 2011-01-21 Preparation method of particles composed of chitosan and fatty acid for stabilization of vitamin C derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020080096130A Division KR101077050B1 (en) 2008-09-30 2008-09-30 Preparation method of particles composed of chitosan and fatty acid for stabilization of vitamin C derivatives

Publications (2)

Publication Number Publication Date
KR20110013563A true KR20110013563A (en) 2011-02-09
KR101107641B1 KR101107641B1 (en) 2012-01-25

Family

ID=43773032

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020110006370A KR101107641B1 (en) 2011-01-21 2011-01-21 Preparation method of particles composed of chitosan and fatty acid for stabilization of vitamin C derivatives

Country Status (1)

Country Link
KR (1) KR101107641B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3042387A1 (en) * 2015-10-20 2017-04-21 Ynsect PRESERVATION OF WATER-SOLUBLE VITAMINS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100511011B1 (en) * 2003-12-03 2005-08-30 학교법인 영남학원 Moisturizing Chitosan-hydroxy acid Complex Compound and Composition of Their Aqueous Solution

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100511011B1 (en) * 2003-12-03 2005-08-30 학교법인 영남학원 Moisturizing Chitosan-hydroxy acid Complex Compound and Composition of Their Aqueous Solution

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Carbohydrate Polymers Vol.29, pp.309-316(1996.)* *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3042387A1 (en) * 2015-10-20 2017-04-21 Ynsect PRESERVATION OF WATER-SOLUBLE VITAMINS
WO2017068278A1 (en) * 2015-10-20 2017-04-27 Ynsect Preservation of water-soluble vitamins

Also Published As

Publication number Publication date
KR101107641B1 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
Hu et al. Formation of self-assembled polyelectrolyte complex hydrogel derived from salecan and chitosan for sustained release of Vitamin C
Wang et al. Redox-responsive blend hydrogel films based on carboxymethyl cellulose/chitosan microspheres as dual delivery carrier
Pal et al. Biopolymers in controlled-release delivery systems
Zhu et al. Nanogels fabricated by lysozyme and sodium carboxymethyl cellulose for 5-fluorouracil controlled release
US20190008775A1 (en) Method for Preparing Modified Sodium Alginate Embolization Microsphere
Khan et al. Chitosan-based polymer matrix for pharmaceutical excipients and drug delivery
WO2019139380A1 (en) Vitamin c-containing polycaprolactone microsphere filler and preparation method therefor
Sharma et al. A propitious role of marine sourced polysaccharides: Drug delivery and biomedical applications
Zhang et al. Imprinted-like biopolymeric micelles as efficient nanovehicles for curcumin delivery
CN110801431A (en) Construction and application of core-shell type intelligent nano delivery system
RU2710074C1 (en) Hydrogel water-soluble composition based on hyaluronic acid and polyvalent metal ions and a method for production thereof
EP3638214B1 (en) Nanoparticles as delivery vehicles of active ingredients and methods for the production thereof
Khalid et al. Polysaccharide chemistry in drug delivery, endocrinology, and vaccines
Ganie et al. Recent innovations in the strategies for the functionalization of chitosan, pectin, alginate, hyaluronic acid, dextran and inulin biomaterials for anticancer applications-a review
Mu et al. Progress in chitin/chitosan and their derivatives for biomedical applications: Where we stand
Galasso et al. Marine polysaccharides, proteins, lipids, and silica for drug delivery systems: A review
KR101107641B1 (en) Preparation method of particles composed of chitosan and fatty acid for stabilization of vitamin C derivatives
KR20170132052A (en) Cosmetic composition having whitening activity containing vitamine C nano particle
KR101077050B1 (en) Preparation method of particles composed of chitosan and fatty acid for stabilization of vitamin C derivatives
Mukherjee et al. Guar gum-based nanomaterials in drug delivery and biomedical applications
Ruiz-Dávila et al. Core-shell chitosan/Porphyridium-exopolysaccharide microgels: Synthesis, properties, and biological evaluation
WO2017010518A1 (en) Drug sustained-release carrier and method for producing same
Derman et al. Poly (N-vinyl-2-pyrrolidone-co-acrylic acid)-bovine serum albumin complex formation studied by HPLC and UV/vis spectroscopy
Jain et al. Peptide and protein delivery through acacia, tragacanth, and ghatti gum
CN107550754B (en) Method for preparing antioxidant composite nano particles by photocatalytic polymerization

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20150112

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20160112

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20170111

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20180112

Year of fee payment: 7